A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038
Recruiting
The purpose of this study is to assess the safety and efficacy of AZD0486 administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Research Site, Boston, Massachusetts +49 locations
Conditions: Chronic Lymphocytic Leukaemia, Small Lymphocytic Leukaemia, Mantle-cell Lymphoma, Large B-cell Lymphoma, B-cell Non-Hodgkin Lymphoma
Register for Updates
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
NCT03420963
Recruiting
This phase I trial studies the side effects and best dose of cord blood-derived expanded allogeneic natural killer cells (donor natural killer \[NK\] cells) and how well they work when given together with cyclophosphamide and etoposide in treating children and young adults with solid tumors that have come back (relapsed) or that do not respond to treatment (refractory). NK cells, white blood cells important to the immune system, are donated/collected from cord blood collected at birth from healt... Read More
Gender:
ALL
Ages:
Between 12 months and 40 years
Trial Updated:
02/13/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Recurrent Lip and Oral Cavity Carcinoma, Recurrent Malignant Endocrine Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Male Reproductive System Neoplasm, Recurrent Malignant Mesothelioma, Recurrent Malignant Neoplasm of Multiple Primary Sites, Recurrent Malignant Oral Neoplasm, Recurrent Malignant Pharyngeal Neoplasm, Recurrent Malignant Skin Neoplasm, Recurrent Malignant Soft Tissue Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Thyroid Gland Neoplasm, Recurrent Malignant Urinary System Neoplasm, Refractory Cutaneous Melanoma, Refractory Malignant Bone Neoplasm, Refractory Malignant Endocrine Neoplasm, Refractory Malignant Female Reproductive System Neoplasm, Refractory Malignant Male Reproductive System Neoplasm, Refractory Malignant Mesothelioma, Refractory Malignant Neoplasm of Multiple Primary Sites, Refractory Malignant Oral Neoplasm, Refractory Malignant Pharyngeal Neoplasm, Refractory Malignant Skin Neoplasm, Refractory Malignant Soft Tissue Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Malignant Thyroid Gland Neoplasm, Refractory Malignant Urinary System Neoplasm, Recurrent Cutaneous Melanoma
Register for Updates
Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma
NCT02298348
Active Not Recruiting
This study will combine three drugs: sorafenib, cyclophosphamide and topotecan. Adding sorafenib to cyclophosphamide and topotecan may increase the effectiveness of this combination. The investigators first need to find out the highest dose of sorafenib that can be given safely together with cyclophosphamide and topotecan. This is the first study to test giving these three drugs together and will help determine the highest dose of sorafenib that can safely be given together with cyclophosphamid... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
02/13/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California +11 locations
Conditions: Neuroblastoma
Register for Updates
'ADVANCE' (A Pilot Trial)
NCT03858322
Active Not Recruiting
This study is being conducted to carefully study how chemotherapy is tolerated in group of patients age 70.
Gender:
ALL
Ages:
70 years and above
Trial Updated:
02/12/2025
Locations: City of Hope National Medical Center, Duarte, California +4 locations
Conditions: Breast Cancer
Register for Updates
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
NCT04304144
Completed
AL amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract. The primary purpose of this study is to determine the recommended dose of CAEL-101 to facilitate progression of further clinical trials and evaluate safety and tolerability o... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/12/2025
Locations: Research Site, Stanford, California +2 locations
Conditions: AL Amyloidosis
Register for Updates
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
NCT01415882
Active Not Recruiting
This phase II trial studies how well ixazomib citrate works in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) but is not resistant to bortezomib (refractory). Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Register for Updates
A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)
NCT05040568
Active Not Recruiting
A study of immunotherapy with expanded CB-NK cells in combination with cetuximab, to evaluate activity against minimal residual disease in patients with colon cancer that have completed adjuvant treatment but are positive for ctDNA
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Colon Cancer, Resected Stage
Register for Updates
Siplizumab for Sickle Cell Disease Transplant
NCT06078696
Recruiting
The purpose of this study is to find out whether siplizumab is safe and effective for patients with SCD undergoing an allogeneic transplant and to prevent development of Graft versus Host Disease (GVHD) and graft failure. The main goals of this study are : * To determine if acute GVHD occurs and how severe the acute GVHD is in subjects receiving the study drug * To determine if graft failure occurs in subjects receiving the study drugs In this study, participants will receive 5 infusions of th... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
02/11/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Anemia, Sickle Cell
Register for Updates
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
NCT03850366
Recruiting
Now haplo stem cell transplant using bone marrow or peripheral blood is becoming more feasible with better regimens to prevent graft versus host disease (GVHD) like post transplant cyclophosphamide , tacrolimus, mycophenolate . Recently Bortezomib has also been shown to inhibit dendritic cells maturation and function and possesses a number of other favorable immunomodulatory effect that can prevent GVHD and help enhance immune reconstitution. this study is to assess the engraftment rate in patie... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/07/2025
Locations: Henry Ford hospital, Detroit, Michigan
Conditions: Hematological Malignancy
Register for Updates
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
NCT03755804
Recruiting
This is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherapy regimens will be based on risk group assignment. Low-risk and intermediate- risk patients will be treated with bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine, and prednisone (BEABOVP) chemotherapy. High-risk patients will receive Adcetris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxo... Read More
Gender:
ALL
Ages:
25 years and below
Trial Updated:
02/06/2025
Locations: Lucile Packard Children's Hospital Stanford University, Palo Alto, California +7 locations
Conditions: Hodgkin Lymphoma
Register for Updates
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
NCT04023669
Completed
SJELIOT is a phase 1 trial that aims to explore the combination of prexasertib with established DNA-damaging agents used in medulloblastoma to evaluate tolerance and pharmacokinetics in recurrent or refractory disease. Additionally, a small expansion cohort will be incorporated into the trial at the combination MTD/RP2D (maximum tolerated dose/recommended phase two dose) to detect a preliminary efficacy signal. Stratum A: Prexasertib and Cyclophosphamide Primary Objectives * To determine the... Read More
Gender:
ALL
Ages:
Between 1 year and 24 years
Trial Updated:
02/06/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory, Brain Tumor, Pediatric, Medulloblastoma, Medulloblastoma Recurrent, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, Non-WNT/Non-SHH, Group 3, Medulloblastoma, Non-WNT/Non-SHH, Group 4, Brain Cancer, CNS Cancer, CNS Tumor, CNS Neoplasm
Register for Updates
T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma
NCT03602612
Active Not Recruiting
Background: Multiple myeloma is a cancer of the blood plasma cells. It usually becomes resistant to standard treatments. Researchers have developed a procedure called gene therapy. It uses a person's own T cells, which are part of the immune system. The cells are changed in a lab and then returned to the person. Researchers hope the changed T cells will be better at recognizing and killing tumor cells. Objective: To test the safety of giving changed T cells to people with multiple myeloma. E... Read More
Gender:
ALL
Ages:
Between 18 years and 73 years
Trial Updated:
02/06/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Myeloma-Multiple, Myeloma, Plasma-Cell
Register for Updates